Tatsuya Yoshida

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 30

Top Topics

Squamous Cell Carcinoma

Tyrosine Kinase

Chronic Myeloid Leukemia

Top Venues

Thoracic cancer

British journal of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Japanese journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, Maria Eugenia Olmedo, Michael J Boyer, Kai He, Neeltje Steeghs, Hiroki Izumi, Melissa Lynne Johnson, Tatsuya Yoshida, Hasna Bouchaab, Hossein Borghaei, Enriqueta Felip Font, Philipp J Jost, Shirish M Gadgeel, Xi Chen, Youfei Yu, Pablo Martinez, Amanda Parkes, Luis G Paz-Ares
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Akiko Tamura, Ryoko Inaba Higashiyama, Tatsuya Yoshida, Yaya Satozono, Yuichiro Ohe
Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient. Thoracic cancer 15 (18) (2024)
Toru Imai, Tatsuya Yoshida, Yuichiro Ohe
Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report. Thoracic cancer 15 (9) (2024)
Akiko Tamura, Ryoko Inaba Higashiyama, Tatsuya Yoshida, Yaya Satozono, Yuichiro Ohe
Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient. Thoracic cancer (2024)
Toru Imai, Tatsuya Yoshida, Yuichiro Ohe
Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report. Thoracic cancer (2024)
Akiko Tamura, Ryoko Inaba Higashiyama, Tatsuya Yoshida, Yaya Satozono, Yuichiro Ohe
Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient. Thoracic cancer 15 (18) (2024)
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, Ryoko Seki, Noboru Yamamoto
Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors. Cancer research communications (2024)
Akiko Tamura, Ryoko Inaba Higashiyama, Tatsuya Yoshida, Yaya Satozono, Yuichiro Ohe
Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient. Thoracic cancer (2024)
Toru Imai, Tatsuya Yoshida, Yuichiro Ohe
Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report. Thoracic cancer 15 (9) (2024)
Akiko Tamura, Ryoko Inaba Higashiyama, Tatsuya Yoshida, Yaya Satozono, Yuichiro Ohe
Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient. Thoracic cancer (2024)
Akiko Tamura, Ryoko Inaba Higashiyama, Tatsuya Yoshida, Yaya Satozono, Yuichiro Ohe
Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient. Thoracic cancer 15 (18) (2024)
Toru Imai, Tatsuya Yoshida, Yuichiro Ohe
Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report. Thoracic cancer 15 (9) (2024)
Luis G Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael J Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa Lynne Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemí Reguart, Tatsuya Yoshida, Kai He, Shirish M Gadgeel, Enriqueta Felip Font, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek Kunle Owonikoko
Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Shigehiro Yagishita, Tatsuya Imabayashi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Masaya Yotsukura, Yukihiro Yoshida, Kazuo Nakagawa, Katsuhiko Naoki, Takaaki Tsuchida, Ryuji Hamamoto, Noboru Yamamoto, Noriko Motoi, Takashi Kohno, Shun-Ichi Watanabe, Yuichiro Ohe
Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer. British journal of cancer (2023)
Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto, Koichi Goto, Nobuyuki Yamamoto, Yuichiro Ohe, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Kazuhiko Nakagawa
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. Cancer science (2023)
Luis G Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael J Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa Lynne Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemí Reguart, Tatsuya Yoshida, Kai He, Shirish M Gadgeel, Enriqueta Felip Font, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek Kunle Owonikoko
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Masahiro Torasawa, Hidehito Horinouchi, Shigehiro Yagishita, Hirofumi Utsumi, Keitaro Okuda, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Saori Murata, Sawako Kaku, Kae Okuma, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Jun Araya, Yuichiro Ohe, Yu Fujita
Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles. Thoracic cancer (2023)
Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Shigehiro Yagishita, Tatsuya Imabayashi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Masaya Yotsukura, Yukihiro Yoshida, Kazuo Nakagawa, Katsuhiko Naoki, Takaaki Tsuchida, Ryuji Hamamoto, Noboru Yamamoto, Noriko Motoi, Takashi Kohno, Shun-Ichi Watanabe, Yuichiro Ohe
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer. British journal of cancer (2023)
Tomoyuki Satake, Shunsuke Kondo, Noriko Tanabe, Takaaki Mizuno, Yuki Katsuya, Jun Sato, Takafumi Koyama, Tatsuya Yoshida, Makoto Hirata, Noboru Yamamoto
Pathogenic germline variants in BRCA1/2 and p53 identified by real-world comprehensive cancer genome profiling tests in Asian patients. Cancer research communications (2023)
Masahiro Torasawa, Tatsuya Yoshida, Yuki Takeyasu, Yukiko Shimoda, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Kazuhisa Takahashi, Yuichiro Ohe
Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients. Cancer medicine (2023)
Tomoaki Nakamura, Yuki Takeyasu, Tatsuya Yoshida, Ken Ohashi, Yuichiro Ohe
End-of-life impact of concurrent diabetes mellitus and adrenal insufficiency as immune-related adverse events in an advanced non-small cell lung cancer patient. Thoracic cancer 13 (21) (2022)
Rumi Nishimura, Tatsuya Yoshida, Masahiro Torasawa, Tairo Kashihara, Yuichiro Ohe
Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report. Thoracic cancer (2022)
Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Performance of Japanese patients in registrational studies. Japanese journal of clinical oncology 52 (1) (2022)
Clara So, Tatsuya Yoshida, Takaaki Mizuno, Yasushi Yatabe, Yuichiro Ohe
Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report. Thoracic cancer 13 (9) (2022)
Hitomi Jo, Tatsuya Yoshida, Hidehito Horinouchi, Shigehiro Yagishita, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Noboru Yamamoto, Kazuhisa Takahashi, Noriko Motoi, Yuichiro Ohe
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab. Cancer immunology, immunotherapy : CII (2021)
Tatsuya Yoshida, Junya Ichikawa, Iulia Giuroiu, Andressa S Laino, Yuhan Hao, Michelle Krogsgaard, Melinda Vassallo, David M Woods, F Stephen Hodi, Jeffrey Weber
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. Journal for immunotherapy of cancer 8 (1) (2021)
Takaaki Mizuno, Tatsuya Yoshida, Kuniko Sunami, Takafumi Koyama, Natsuko Okita, Takashi Kubo, Kazuki Sudo, Tatsunori Shimoi, Hideki Ueno, Eiko Saito, Kota Katanoda, Taro Shibata, Kan Yonemori, Takuji Okusaka, Narikazu Boku, Yuichiro Ohe, Yukihiko Hiroshima, Makoto Ueno, Yasutoshi Kuboki, Toshihiko Doi, Kenichi Nakamura, Takashi Kohno, Yasushi Yatabe, Noboru Yamamoto
Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Japanese journal of clinical oncology 51 (12) (2021)
Masayuki Shirasawa, Tatsuya Yoshida, Hidehito Horinouchi, Shigehisa Kitano, Sayaka Arakawa, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Shintaro Kanda, Reiko Watanabe, Noboru Yamamoto, Shun-Ichi Watanabe, Yuichiro Ohe, Noriko Motoi
Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment. British journal of cancer 124 (5) (2020)
Ryoko Inaba-Higashiyama, Tatsuya Yoshida, Hitomi Jo, Masayuki Shirasawa, Noriko Motoi, Yuichiro Ohe
Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case series. Thoracic cancer 11 (12) (2020)
Shuji Murakami, Ryota Shibaki, Yuji Matsumoto, Tatsuya Yoshida, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Thoracic cancer 11 (12) (2020)